NASDAQ:NVCR NovoCure (NVCR) Stock Price, News & Analysis $11.13 -0.38 (-3.30%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$11.38 +0.24 (+2.20%) As of 08/8/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About NovoCure Stock (NASDAQ:NVCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NovoCure alerts:Sign Up Key Stats Today's Range$11.11▼$11.6950-Day Range$10.97▼$18.4652-Week Range$10.91▼$34.13Volume1.37 million shsAverage Volume2.07 million shsMarket Capitalization$1.24 billionP/E RatioN/ADividend YieldN/APrice Target$28.79Consensus RatingModerate Buy Company Overview NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. Read More NovoCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreNVCR MarketRank™: NovoCure scored higher than 90% of companies evaluated by MarketBeat, and ranked 105th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingNovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageNovoCure has only been the subject of 3 research reports in the past 90 days.Read more about NovoCure's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for NovoCure are expected to decrease in the coming year, from ($1.30) to ($1.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovoCure is -7.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovoCure is -7.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoCure has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.99% of the float of NovoCure has been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NovoCure has recently decreased by 5.74%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovoCure does not currently pay a dividend.Dividend GrowthNovoCure does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.15 Percentage of Shares Shorted4.99% of the float of NovoCure has been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NovoCure has recently decreased by 5.74%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.67 News SentimentNovoCure has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NovoCure this week, compared to 5 articles on an average week.Search Interest6 people have searched for NVCR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added NovoCure to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, NovoCure insiders have bought more of their company's stock than they have sold. Specifically, they have bought $231,800.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.52% of the stock of NovoCure is held by insiders.Percentage Held by Institutions84.61% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NovoCure's insider trading history. Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address NVCR Stock News HeadlinesChristoph Brackmann Buys 20,000 Shares of NovoCure Limited (NASDAQ:NVCR) StockJuly 31, 2025 | insidertrades.comNovoCure (NASDAQ:NVCR) Trading Up 9.3% Following Insider Buying ActivityAugust 2, 2025 | americanbankingnews.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!). | Weiss Ratings (Ad)NovoCure: Cash Burn, A Costly Launch, And A Maturing Business Signal More Pain AheadAugust 1, 2025 | seekingalpha.comNovoCure's Wearable Oncology Edge And Compelling ValuationJuly 30, 2025 | seekingalpha.comNovoCure Limited (NASDAQ:NVCR) Q2 2025 Earnings Call TranscriptJuly 29, 2025 | msn.comWells Fargo Downgrades NovoCure (NVCR)July 26, 2025 | msn.comNovoCure Q2 Revenue Jumps 6 PercentJuly 25, 2025 | theglobeandmail.comSee More Headlines NVCR Stock Analysis - Frequently Asked Questions How have NVCR shares performed this year? NovoCure's stock was trading at $29.80 at the beginning of 2025. Since then, NVCR shares have decreased by 62.7% and is now trading at $11.13. How were NovoCure's earnings last quarter? NovoCure Limited (NASDAQ:NVCR) released its earnings results on Thursday, July, 24th. The medical equipment provider reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.03. The firm's revenue for the quarter was up 5.6% compared to the same quarter last year. Read the conference call transcript. Who are NovoCure's major shareholders? Top institutional investors of NovoCure include Geode Capital Management LLC (2.19%), Connor Clark & Lunn Investment Management Ltd. (0.55%), Emerald Advisers LLC (0.41%) and Emerald Mutual Fund Advisers Trust (0.20%). Insiders that own company stock include Wilhelmus Cm Groenhuysen, Ashley Cordova, W Anthony Vernon, Frank X Leonard, Christoph Brackmann, Pritesh Shah, Michal Nath Puri, Uri Weinberg, Asaf Danziger and Mukund Paravasthu. View institutional ownership trends. How do I buy shares of NovoCure? Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NovoCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that NovoCure investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Chembio Diagnostics (CEMI), Tesla (TSLA), Advanced Micro Devices (AMD) and Intel (INTC). Company Calendar Last Earnings7/24/2025Today8/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolNASDAQ:NVCR CIK1645113 Webwww.novocure.com Phone441534756700FaxN/AEmployees1,488Year FoundedN/APrice Target and Rating Average Price Target for NovoCure$28.79 High Price Target$38.00 Low Price Target$14.50 Potential Upside/Downside+158.6%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$168.63 million Net Margins-27.13% Pretax Margin-22.54% Return on Equity-47.74% Return on Assets-13.79% Debt Debt-to-Equity Ratio0.28 Current Ratio1.45 Quick Ratio1.39 Sales & Book Value Annual Sales$605.22 million Price / Sales2.06 Cash FlowN/A Price / Cash FlowN/A Book Value$3.13 per share Price / Book3.56Miscellaneous Outstanding Shares111,800,000Free Float105,628,000Market Cap$1.24 billion OptionableOptionable Beta0.61 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:NVCR) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.